Actively Recruiting
The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program
Led by University of Alberta · Updated on 2025-09-17
240
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
Sponsors
U
University of Alberta
Lead Sponsor
C
Covenant Health, Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
Neonatal Abstinence Syndrome (NAS), is a common and costly problem in Alberta that affects approximately 250 babies per year exposed to drugs during pregnancy. Unfortunately, this has become more common in the last 10 years. Babies with NAS can be very difficult to care for with poor feeding, diarrhea, and extreme irritability. These babies often receive specialized care and medications in the Neonatal Intensive Care Unit (NICU), which leads to separation of mothers and babies at a time when it is most important that they be together. This separation is traumatic for families and expensive for the health and foster care systems, as babies often end up being cared for by governmental agencies. Recent research has shown that keeping mothers and babies together in a quiet, supportive environment in hospital, called 'rooming in', leads to a decreased need for NICU admission, decreased amount of time spent in the NICU, increased rates of breastfeeding, and an increase in babies going home with their mothers. This project will systematically introduce a program of 'rooming-in' to hospitals in Alberta to determine if the investigators can improve NAS care provided to babies and mothers. The goal is to decrease NICU admission and length of stay, increase the number of babies going home with mothers, increase breastfeeding rates, and increase the number of women enrolled in supportive programs for substance use. The investigators will also determine if this rooming-in model of care decreases health and societal costs associated with caring for babies with NAS.
CONDITIONS
Official Title
The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infants born at more than 36 weeks gestation to mothers who report opiate use during pregnancy or who are in an opioid dependency program
- Infants admitted to a participating hospital in the implementation project
You will not qualify if you...
- Infants born before 36 weeks gestation
- Infants weighing less than 2000 grams at birth
- Infants with congenital anomalies expected to require NICU admission
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alberta
Edmonton, Alberta, Canada, T6G 2C8
Actively Recruiting
Research Team
M
Matt Hicks, MD, PhD
CONTACT
O
Osnat Wine, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here